MX2017005807A - Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. - Google Patents

Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.

Info

Publication number
MX2017005807A
MX2017005807A MX2017005807A MX2017005807A MX2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A
Authority
MX
Mexico
Prior art keywords
treatment
multipeptides
terapeutic
specific immunotherapy
cerebral metastasis
Prior art date
Application number
MX2017005807A
Other languages
English (en)
Other versions
MX386458B (es
Inventor
Costantini Dominique
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MX2017005807A publication Critical patent/MX2017005807A/es
Publication of MX386458B publication Critical patent/MX386458B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición de vacuna de péptidos OSE-2101 para el tratamiento de metástasis cerebrales en pacientes positivos para HLA-A2.
MX2017005807A 2014-11-06 2014-11-06 Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales. MX386458B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/073975 WO2016070928A1 (en) 2014-11-06 2014-11-06 Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis

Publications (2)

Publication Number Publication Date
MX2017005807A true MX2017005807A (es) 2017-08-02
MX386458B MX386458B (es) 2025-03-18

Family

ID=51871025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005807A MX386458B (es) 2014-11-06 2014-11-06 Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales.

Country Status (16)

Country Link
US (1) US10434157B2 (es)
EP (1) EP3215184B1 (es)
JP (1) JP6474893B2 (es)
KR (1) KR102043725B1 (es)
CN (1) CN107073087B (es)
AR (1) AR102555A1 (es)
AU (1) AU2014410466B2 (es)
BR (1) BR112017009358A2 (es)
CA (1) CA2963184C (es)
EA (1) EA037271B1 (es)
ES (1) ES2874006T3 (es)
IL (1) IL250576B (es)
MX (1) MX386458B (es)
NZ (1) NZ729514A (es)
TW (1) TWI703982B (es)
WO (1) WO2016070928A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6654207B2 (ja) * 2015-06-29 2020-02-26 オーエスイー・イミュノセラピューティクス 短鎖ペプチド抗腫瘍ワクチンを用いて早期のｔメモリー応答を誘発する方法。
CN114917189B (zh) 2017-01-25 2024-05-14 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
AU2017440798C1 (en) * 2017-11-27 2026-01-15 Ose Immunotherapeutics Improved treatment of cancer
CN109988748A (zh) * 2017-12-29 2019-07-09 深圳华大生命科学研究院 一种从til筛选肿瘤特异性t细胞的方法
MX390775B (es) 2018-12-21 2025-03-21 Ose Immunotherapeutics Anticuerpo humanizado anti-pd-1 humana
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
RU2408605C2 (ru) * 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
CN103145803B (zh) * 2012-12-13 2014-03-12 东南大学 一种与乳腺癌脑转移细胞特异性结合的多肽

Also Published As

Publication number Publication date
MX386458B (es) 2025-03-18
CN107073087A (zh) 2017-08-18
AU2014410466B2 (en) 2019-09-12
EA201790990A1 (ru) 2017-09-29
BR112017009358A2 (pt) 2017-12-19
JP6474893B2 (ja) 2019-02-27
AU2014410466A1 (en) 2017-03-30
KR20170098811A (ko) 2017-08-30
WO2016070928A1 (en) 2016-05-12
IL250576B (en) 2019-09-26
CN107073087B (zh) 2020-09-08
ES2874006T3 (es) 2021-11-04
JP2017533898A (ja) 2017-11-16
CA2963184A1 (en) 2016-05-12
TWI703982B (zh) 2020-09-11
IL250576A0 (en) 2017-03-30
CA2963184C (en) 2020-11-24
NZ729514A (en) 2019-12-20
EA037271B1 (ru) 2021-03-02
US20170319672A1 (en) 2017-11-09
EP3215184B1 (en) 2021-03-03
AR102555A1 (es) 2017-03-08
KR102043725B1 (ko) 2019-11-13
US10434157B2 (en) 2019-10-08
TW201625287A (zh) 2016-07-16
EP3215184A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
EA201691582A1 (ru) Новые фармацевтические препараты
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
SV2016005267A (es) Terapias de combinación con anticuerpos anti-cd38
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201691974A1 (ru) Антитела против ox40 и способы их применения
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
GEAP202114450A (en) Anti-tigit antibodies
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
IL247857A0 (en) Dynamic enablement of several processes at the same time
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
MX2017005807A (es) Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.
DK2897382T3 (da) Forbedring af binaural kilde
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
PT3215132T (pt) Amantadina para melhorar a marcha em esclerose múltipla
BR112016019389A8 (pt) Vacina, e, peptídeo
DK3578179T3 (da) Process for the preparation of cyclic depsipeptides
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
MX382659B (es) Proceso para la preparación de derivados de tiazol.
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
DOP2017000001A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer